Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$12.2 million.

  • Rocket Pharmaceuticals' Change in Accured Expenses fell 486.22% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.6 million, marking a year-over-year decrease of 140.90%. This contributed to the annual value of $6.1 million for FY2024, which is 40.21% down from last year.
  • Rocket Pharmaceuticals' Change in Accured Expenses amounted to -$12.2 million in Q3 2025, which was down 250.81% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Change in Accured Expenses ranged from a high of $15.8 million in Q4 2023 and a low of -$16.0 million during Q2 2021.
  • In the last 3 years, Rocket Pharmaceuticals' Change in Accured Expenses had a median value of $774,000 in 2024 and averaged $620,909.
  • The largest annual percentage gain for Rocket Pharmaceuticals' Change in Accured Expenses in the last 5 years was 534.12% (2023), contrasted with its biggest fall of 1,478.41% (2023).
  • Over the past 5 years, Rocket Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at -$2.0 million in 2021, then spiked by 225.19% to $2.5 million in 2022, then skyrocketed by 534.12% to $15.8 million in 2023, then crashed by 95.09% to $774,000 in 2024, then crashed by 486.22% to -$12.2 million in 2025.
  • Its Change in Accured Expenses was -$12.2 million in Q3 2025, compared to $8.1 million in Q2 2025 and -$5.3 million in Q1 2025.